1.67Open1.67Pre Close0 Volume23 Open Interest12.50Strike Price0.00Turnover345.29%IV17.50%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry1.67Extrinsic Value100Contract SizeAmericanOptions Type0.5405Delta0.0853Gamma7.22Leverage Ratio-0.2160Theta0.0006Rho3.90Eff Leverage0.0054Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addres...
No comment yet